Sigma Planning Corp Has $631,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Sigma Planning Corp trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 29.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,227 shares of the company’s stock after selling 1,334 shares during the quarter. Sigma Planning Corp’s holdings in Zoetis were worth $631,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. First Personal Financial Services acquired a new position in shares of Zoetis in the third quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the third quarter worth approximately $33,000. Quarry LP lifted its stake in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the period. LRI Investments LLC acquired a new position in shares of Zoetis in the first quarter worth approximately $43,000. Finally, Fortitude Family Office LLC lifted its stake in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after acquiring an additional 222 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus price target of $221.44.

Zoetis Trading Down 1.4 %

NYSE ZTS opened at $174.63 on Friday. The company has a market cap of $78.79 billion, a price-to-earnings ratio of 32.83, a P/E/G ratio of 2.67 and a beta of 0.90. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The business has a 50 day moving average price of $187.61 and a 200-day moving average price of $180.02. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.36 earnings per share. As a group, equities analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.99%. Zoetis’s dividend payout ratio is 32.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.